Perceptive Advisors’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-200,791
| Closed | -$9M | – | 128 |
|
|
2025
Q4 | $9M | Hold |
200,791
| – | – | 0.16% | 82 |
|
|
2025
Q3 | $8.06M | Hold |
200,791
| – | – | 0.23% | 63 |
|
|
2025
Q2 | $6.28M | Sell |
200,791
-124,533
| -38% | -$4.06M | 0.23% | 62 |
|
|
2025
Q1 | $10.9M | Hold |
325,324
| – | – | 0.39% | 50 |
|
|
2024
Q4 | $12.8M | Sell |
325,324
-199,606
| -38% | -$8.25M | 0.35% | 53 |
|
|
2024
Q3 | $20.7M | Sell |
524,930
-58,326
| -10% | -$2.35M | 0.44% | 57 |
|
|
2024
Q2 | $22.7M | Sell |
583,256
-308,952
| -35% | -$12.3M | 0.55% | 51 |
|
|
2024
Q1 | $38.4M | Sell |
892,208
-208,540
| -19% | -$9.59M | 0.67% | 48 |
|
|
2023
Q4 | $50.7M | Buy |
1,100,748
+483,248
| +78% | +$17.1M | 1.13% | 29 |
|
|
2023
Q3 | $21.1M | Sell |
617,500
-605,877
| -50% | -$22.7M | 0.7% | 42 |
|
|
2023
Q2 | $47.1M | Sell |
1,223,377
-608,797
| -33% | -$24.2M | 1.36% | 21 |
|
|
2023
Q1 | $65.6M | Sell |
1,832,174
-89,099
| -5% | -$3.29M | 1.94% | 12 |
|
|
2022
Q4 | $75.8M | Sell |
1,921,273
-201,262
| -9% | -$7.33M | 2.13% | 15 |
|
|
2022
Q3 | $76.6M | Hold |
2,122,535
| – | – | 2.22% | 14 |
|
|
2022
Q2 | $64.6M | Sell |
2,122,535
-288,912
| -12% | -$8.74M | 2.02% | 11 |
|
|
2022
Q1 | $73.7M | Hold |
2,411,447
| – | – | 1.48% | 19 |
|
|
2021
Q4 | $75.3M | Buy |
2,411,447
+389,396
| +19% | +$11.6M | 1.16% | 22 |
|
|
2021
Q3 | $30.9M | Buy |
2,022,051
+343,078
| +20% | +$5.96M | 0.45% | 55 |
|
|
2021
Q2 | $31.3M | Buy |
1,678,973
+1,163,931
| +226% | +$21.5M | 0.41% | 56 |
|
|
2021
Q1 | $9.22M | Buy |
+515,042
| New | +$8.73M | 0.12% | 102 |
|
|
2017
Q3 | – | Sell |
-723,853
| Closed | -$2.28M | – | 153 |
|
|
2017
Q2 | $2.28M | Hold |
723,853
| – | – | 0.11% | 80 |
|
|
2017
Q1 | $2.9M | Sell |
723,853
-16,419
| -2% | -$129K | 0.16% | 76 |
|
|
2016
Q4 | $5.7M | Sell |
740,272
-22,528
| -3% | -$181K | 0.41% | 55 |
|
|
2016
Q3 | $6.18M | Buy |
762,800
+330,000
| +76% | +$2.55M | 0.4% | 60 |
|
|
2016
Q2 | $2.55M | Buy |
432,800
+227,000
| +110% | +$1.56M | 0.18% | 78 |
|
|
2016
Q1 | $1.44M | Hold |
205,800
| – | – | 0.13% | 93 |
|
|
2015
Q4 | $1.66M | Hold |
205,800
| – | – | 0.12% | 79 |
|
|
2015
Q3 | $1.7M | Sell |
205,800
-19,200
| -9% | -$191K | 0.14% | 84 |
|
|
2015
Q2 | $2.59M | Hold |
225,000
| – | – | 0.16% | 90 |
|
|
2015
Q1 | $3.79M | Hold |
225,000
| – | – | 0.29% | 62 |
|
|
2014
Q4 | $4.44M | Buy |
+225,000
| New | +$3.3M | 0.37% | 57 |
|
Other funds holding XENE
ACA
DCM
PCH
Perceptive Advisors's XENE Position: Q1 2026 in Review
Perceptive Advisors sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 200,791 shares — an estimated $9M sold.
Perceptive Advisors first reported a position in XENE in Q4 2014 and held it in 31 quarters. The position peaked at $76.6M in Q3 2022. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.
- Perceptive Advisors reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Perceptive Advisors sold 200,791 Xenon Pharmaceuticals shares in Q1 2026, an estimated $9M.
- Perceptive Advisors first reported a position in Xenon Pharmaceuticals in Q4 2014 and held it in 31 quarters.
- Perceptive Advisors's Xenon Pharmaceuticals position peaked at $76.6M in Q3 2022.
- 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.